tus insignias Rango 52S $123–$186 32% of range Calificación del Analista BUY 36 analysts Precio Objetivo $208 +45% upside P/E 21.0 ROE 22.1% Margen de Beneficio Neto 20.9%

NBIX Instantánea de la Acción Precio, capitalización bursátil, P/E, BPA, ROE, deuda/capital, rango de 52 semanas

03
Precio $143.18
Capitalización Bursátil (MRQ) $14.55B
P/E (TTM) 21.0
BPA (TTM) $6.83
Ingresos (TTM) $3.37B
ROE (TTM) 22.1%
Rango 52S $123–$186

NBIX Gráfico del Precio de la Acción OHLCV diario con indicadores técnicos — desplace, amplíe y personalice su vista

04
rango
barras

La granularidad de las barras se adapta al período seleccionado; pase el ratón sobre el gráfico para ver la apertura/máximo/mínimo/cierre de una barra.

Acerca de Neurocrine Biosciences, Inc. - Common Stock Descripción general de la empresa de Wikipedia

05 · wikidata

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

History

Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.

In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.

In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.

In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.

In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.

Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.

On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.

In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.

In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.

In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.

In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.

In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.

Product pipeline

Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids

Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease

NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist

NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.

Fuente: Wikipedia (Inglés), CC BY-SA 4.0 · Ver en Wikipedia ↗

Wikidata ↗

sectorHealthcare industriaBiotechnology empleados2 500 paísUS

Rendimiento a 10 años Tendencias de ingresos, beneficio neto, márgenes y BPA

06
Ingresos$2.86B
2016-12-31 → 2025-12-31
BPA$4.67
2016-12-31 → 2025-12-31
Flujo de caja libre$749M
2016-12-31 → 2025-12-31
Margen neto20.9%
2016-12-31 → 2025-12-31
Valoración y ratios 07–12

Valoración Ratios P/E, P/S, P/B, EV/EBITDA: ¿está la acción cara o barata?

Métrica Tendencia a 5 años NBIX promedio 5A Mediana de Pares Veredicto
P/E (TTM) 21.0promedio 5A ≈58.9 ≈58.9 19.4 Sobrevalorado
P/S (TTM) 4.3promedio 5A ≈6.5 ≈6.5 7.3 Infravalorado
P/C (MRQ) 3.9promedio 5A ≈5.6 ≈5.6 14.5 Infravalorado
Precio / FCF (TTM) 16.7promedio 5A ≈29.9 ≈29.9 · ·
Precio / Flujo de Caja (TTM) 16.2promedio 5A ≈28.0 ≈28.0 13.6 Sobrevalorado
Precio / Valor Contable Tangible (MRQ) 9.9promedio 5A ≈5.7 ≈5.7 · ·
PEG Ratio (Ratio PEG) ≈9.0 · · ·

La mediana de empresas comparables se calcula sobre una base estandarizada por métrica y puede no coincidir siempre con la base TTM/MRQ que se muestra para esta acción.

valor · ≈ promedio 5A · mediana sectorial · veredicto relativo a la mediana

Historial de Ganancias EPS real vs estimado, sorpresa %, tasa de aciertos, próxima fecha de resultados

14
Sorpresa Media 11.3%
Próximo informe Oct 26, 2026
PeríodoInformeEPS ActualEPS est.Sorpresa
30 de junio de 2026 Jul 28, 2026 $1.39 $1.37 1.5%
31 de marzo de 2026 $1.91 $1.20 59.5%
31 de diciembre de 2025 $1.91 $1.20 59.5%
30 de septiembre de 2025 $2.04 $1.62 26.1%
30 de junio de 2025 $1.06 $0.99 7.0%
31 de marzo de 2025 $0.08 $0.56 -85.6%

Fundamentales Completos Todas las métricas por año — estado de resultados, balance general, flujo de caja

15
Estado de resultados 17
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue $2.86B$2.36B$1.89B$1.49B$1.13B$1.05B$788M$451M$162M$15M$20M$0
Cost of Revenue $52M$34M$40M$23M$14M$10M·$5M$1M$0$0·
R&D Expense ·······$161M$122M$94M$81M$46M
SG&A Expense $1.16B$1.01B$888M$753M$583M$433M$354M$249M$170M$68M$32M$18M
Operating Expenses $2.24B$1.78B$1.64B$1.24B$1.03B$883M$716M$414M$293M$162M$114M$64M
Operating Income $619M$570M$251M$249M$102M$163M$72M$37M$-131M$-147M$-94M$-64M
Interest Expense ··$5M$7M$26M$33M$32M$30M$20M$0$0·
Interest Income ·········$3M$2M$629.0K
Other Non-op $86M$-84M$81M$-35M$-1M$-56M$-26M$-15M$-11M$6M$20.0K$18.0K
Pretax Income $705M$486M$332M$214M$101M$107M$46M$22M$-143M$-141M··
Income Tax $227M$145M$82M$59M$12M$-301M$10M$700.0K$0$0$0$0
Net Income $479M$341M$250M$154M$90M$407M$37M$21M$-143M$-141M$-89M$-61M
EPS (Basic) $4.81$3.40$2.56$1.61$0.95$4.38$0.40$0.23$-1.62$-1.63$-1.05$-0.81
EPS (Diluted) $4.67$3.29$2.47$1.56$0.92$4.16$0.39$0.22$-1.62$-1.63$-1.05$-0.81
Shares (Basic) 99,500,000100,400,00097,700,00095,800,00094,600,00093,100,00091,600,00090,200,00088,089,00086,713,00084,496,00074,577,000
Shares (Diluted) 102,500,000103,700,000101,000,00098,900,00097,900,00097,800,00095,700,00095,400,00088,089,00086,713,00084,496,00074,577,000
EBITDA $619M$570M$251M$249M$102M$163M$72M$37M$-131M$-147M·$-64M
Balance general 28
Métrica Tendencia 202520242023202220212020201920182017201620152014
Cash & Equivalents $713M$233M$251M$263M$341M$187M$112M$142M$255M$83M$74M$31M
Short-term Investments ····$370M$614M$558M$509M$261M$224M$305M$163M
Receivables $687M$479M$439M$350M$186M$157M$127M$57M$31M$0··
Inventory $69M$57M$38M$35M$30M$28M$17M$11M$1M$0··
Prepaid Expense $171M$48M··········
Other Current Assets $116M$64M$98M$79M$46M$30M$17M$19M$7M$3M$5M$4M
Current Assets $2.52B$1.72B$1.61B$1.45B$973M$1.02B$831M$738M$555M$310M$384M$198M
PP&E (Net) $90M$83M$71M$59M$59M$45M$42M$34M$11M$6M$3M$3M
PP&E (Gross) $208M$189M$154M$125M$110M$86M$76M$62M$38M$32M$30M$31M
Accum. Depreciation $118M$106M$83M$66M$52M$42M$34M$28M$28M$26M$27M$29M
Goodwill $6M$6M$6M$5M$0·······
Intangibles $5M$36M$36M$37M$0·······
Other Non-current Assets $49M$52M$50M$25M$4M$6M$0·····
Total Assets $4.63B$3.72B$3.25B$2.37B$2.07B$1.73B$1.31B$993M$818M$365M$475M$243M
Accounts Payable $674M$462M$449M$348M$226M$169M$141M$86M$6M$5M$3M$246.0K
Accrued Liabilities ·········$21M$19M$12M
Current Liabilities $743M$508M$655M$538M$246M$186M$565M$88M$54M$30M$26M$16M
Capital Leases $415M$455M$258M$94M$105M$94M$87M$0····
Deferred Tax $0···········
Other Non-current Liabilities $220M$166M$106M$30M$12M$10M$17M$36M$0$113.0K$221.0K$260.0K
Total Liabilities $1.38B$1.13B$1.02B$661M$698M$608M$669M$512M$445M$50M$50M$34M
Common Stock $100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$100.0K$91.0K$89.0K$87.0K$86.0K$76.0K
Paid-in Capital ···········$1.04B
Retained Earnings $448M$29M$-157M$-407M$-636M$-725M$-1.13B$-1.18B$-1.20B$-1.06B$-915M$-826M
AOCI $13M$6M$7M$-8M$-2M$2M$1M$-2M$-2M$-318.0K$-977.0K$-277.0K
Stockholders' Equity $3.25B$2.59B$2.23B$1.71B$1.37B$1.13B$637M$481M$372M$315M$424M$209M
Liabilities + Equity $4.63B$3.72B$3.25B$2.37B$2.07B$1.73B$1.31B$993M$818M$365M$475M$243M
Shares Outstanding 100,100,00099,400,00098,700,00096,500,00094,900,00093,500,00092,300,00090,797,00088,793,90386,883,30086,262,59476,465,942
Flujo de Efectivo 15
Métrica Tendencia 202520242023202220212020201920182017201620152014
D&A ·······$4M$2M$1M$1M$827.0K
Stock-based Comp $218M$196M$194M$173M$134M$100M$75M$58M$43M$28M$28M$10M
Deferred Tax $164M$-123M$-61M$22M$6M$-311M$0$0····
Amort. of Intangibles $4M$4M$4M$500.0K$0$0······
Operating Cash Flow $783M$595M$390M$339M$256M$228M$147M$101M$-94M$-106M$-38M$-47M
CapEx $34M$38M$28M$16M$23M$11M$15M$25M$7M$4M$2M$2M
Investing Cash Flow $-264M$-127M$-467M$-177M$-130M$4M$-211M$-243M$-251M$113M··
Stock Issued $129M$122M$65M$45M$28M$29M$32M$30M$14M$2M$277M$139M
Stock Repurchased $168M$300M$0$0········
Net Stock Activity $-38M$-178M$65M$45M$28M$29M$27M$30M$14M$2M·$139M
Financing Cash Flow $-38M$-487M$65M$-234M$27M$-158M$32M$30M$517M$2M··
Net Change in Cash $480M$-18M$-12M$-73M$154M$75M$-32M$-112M$171M$9M$43M$-14M
Taxes Paid $81M···········
Free Cash Flow $749M$557M$362M$323M$233M$218M$137M$77M$-101M$-110M·$-49M
Levered FCF ··$358M$318M$210M$92M$112M$47M····
Rentabilidad 7
Métrica Tendencia 202520242023202220212020201920182017201620152014
Operating Margin 21.6%24.2%13.3%16.7%9.0%15.6%9.2%8.2%-81.3%-982.5%··
Net Margin 16.7%14.5%13.2%10.4%7.9%38.9%4.7%4.7%-88.2%-940.6%··
Pretax Margin 24.7%20.6%17.6%14.4%8.9%10.2%5.9%4.8%····
EBITDA Margin 21.6%24.2%13.3%16.7%9.0%15.6%9.2%8.2%-81.3%-982.5%··
ROA 11.5%9.8%8.9%7.0%4.7%26.8%3.2%2.3%-24.1%-33.6%·-30.4%
ROE 16.1%12.9%11.8%9.5%6.6%42.2%6.1%4.5%-41.5%-38.2%·-36.8%
ROIC 12.9%15.5%8.5%10.5%6.6%55.2%9.0%7.4%····
Liquidez y Solvencia 3
Métrica Tendencia 202520242023202220212020201920182017201620152014
Current Ratio 3.43.42.52.74.05.41.58.410.210.2·12.7
Quick Ratio 1.91.41.11.13.65.11.42.210.110.1·12.4
Interest Coverage ··54.535.14.05.02.31.2-6.7···
Eficiencia 3
Métrica Tendencia 202520242023202220212020201920182017201620152014
Asset Turnover 0.70.70.70.70.60.70.70.50.30.0·0.0
Inventory Turnover 0.80.71.10.7···0.8····
Receivables Turnover 4.95.14.85.66.67.48.610.310.4···
Por Acción 5
Métrica Tendencia 202520242023202220212020201920182017201620152014
Book Value / Share $32.50$26.05$22.61$17.70$14.48$12.04$6.90$5.29$4.19$3.62·$2.73
Revenue / Share $27.91$22.71$18.68$15.05$11.58$10.69$8.23$4.73$1.83$0.17·$0.00
Cash Flow / Share $7.64$5.74$3.86$3.43$2.62$2.34$1.59$1.06$-1.07$-1.22·$-0.63
Cash / Share $7.12$2.34$2.54$2.72$3.59$2.00$1.22$1.56$2.87$0.96·$0.41
EPS (TTM) $4.67$3.29$2.47$1.56$0.92$4.16$0.39$0.22$-1.62$-1.63$-1.05$-0.81
Tasas de Crecimiento 9
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue YoY 21.4%24.8%26.8%31.3%8.4%·······
Revenue CAGR 3Y 24.3%27.6%21.7%·········
Revenue CAGR 5Y 22.3%···········
EPS YoY 41.9%33.2%58.3%69.6%-77.9%·······
EPS CAGR 3Y 44.1%52.9%-16.0%·········
EPS CAGR 5Y 2.3%···········
Net Income YoY 40.2%36.7%61.6%72.4%-78.0%·······
Net Income CAGR 3Y 45.8%56.2%-15.0%·········
Net Income CAGR 5Y 3.3%···········
Valoración (TTM) 10
Métrica Tendencia 202520242023202220212020201920182017201620152014
Revenue TTM $2.86B$2.36B$1.89B$1.49B$1.13B$1.05B$788M$451M$162M$15M$20M$0
Net Income TTM $479M$341M$250M$154M$90M$407M$37M$21M$-143M$-141M$-89M$-61M
Market Cap $14.20B$13.57B$13.00B$11.53B$8.08B$8.96B$9.92B$6.48B$6.89B$3.36B·$1.71B
P/E 30.441.553.376.692.623.0275.6324.6-47.9-23.7-53.9-27.6
P/S 5.05.86.97.77.18.612.614.442.6224.2··
P/B 4.45.25.86.75.98.015.613.518.510.7·8.2
P / Tangible Book 4.45.35.96.95.98.0······
P / Cash Flow 18.122.833.434.031.539.265.264.0-73.0-31.7·-36.2
P / FCF 19.024.436.035.734.741.272.284.7-68.0-30.5·-35.0
Earnings Yield 3.3%2.4%1.9%1.3%1.1%4.3%0.36%0.31%-2.1%-4.2%-1.9%-3.6%

Período más reciente a la izquierda · valores nulos mostrados como ·

Estados Financieros Estado de resultados, balance general, flujo de caja — anual, últimos 5 años

16
Métrica 2025-12-312024-12-312023-12-312022-12-312021-12-31
Ingresos $2.86B $2.36B $1.89B $1.49B $1.13B
Margen Operativo % 21.6% 24.2% 13.3% 16.7% 9.0%
Beneficio neto $479M $341M $250M $154M $90M
EPS Diluido $4.67 $3.29 $2.47 $1.56 $0.92

Propietarios institucionales (13F) 825 declarantes · $18.1B total · A fecha de 30 de septiembre de 2026

17

Instituciones que informan tener esta acción en su Formulario 13F trimestral de la SEC. Solo posiciones largas; un solo presentador puede aparecer dos veces para tramos de opciones separados. Las patas de put/call de compensación grandes suelen reflejar la creación de mercado o el inventario cubierto, no la convicción direccional.

Tenedores 825
Valor en tenencia $18.1B
Nuevas posiciones 148
Posiciones cerradas 62
Actividad institucional — Q2 2026 vs trimestre anterior
Nuevas posiciones Posiciones cerradas Aumentado Disminuido Cambio neto de acciones
148 (+50 vs trimestre anterior) 62 (-36 vs trimestre anterior) 317 (+16 vs trimestre anterior) 226 (+12 vs trimestre anterior) +587K

Comparado con Q1 2026. Las presentaciones del Formulario 13F de la SEC vencen dentro de los 45 días posteriores al final del trimestre, más un pequeño margen para los presentadores tardíos; los trimestres que aún se encuentran dentro de esa ventana se omiten en favor del par más reciente completamente reportado.

Institución Valor Acciones % de 13F rastreadas Tipo
BlackRock, Inc. $2 310 885 707 13 711 607 12,75% Acciones
VANGUARD GROUP INC $1 375 793 692 9 700 301 7,59% Acciones
JPMORGAN CHASE & CO $1 088 569 109 6 398 674 6,01% Acciones
Dodge & Cox $941 218 594 5 584 707 5,19% Acciones
VANGUARD PORTFOLIO MANAGEMENT LLC $838 307 078 4 974 083 4,63% Acciones
VANGUARD CAPITAL MANAGEMENT LLC $766 048 708 4 545 339 4,23% Acciones
STATE STREET CORP $739 126 759 4 385 598 4,08% Acciones
AQR CAPITAL MANAGEMENT LLC $643 472 716 3 818 037 3,55% Acciones
RENAISSANCE TECHNOLOGIES LLC $393 680 402 2 335 897 2,17% Acciones
GEODE CAPITAL MANAGEMENT, LLC $359 607 676 2 138 777 1,98% Acciones
TWO SIGMA INVESTMENTS, LP $349 922 479 2 076 260 1,93% Acciones
Vestal Point Capital, LP $316 845 800 1 880 000 1,75% Acciones
BNP PARIBAS ASSET MANAGEMENT Holding S.A. $251 858 951 1 494 259 1,39% Acciones
MORGAN STANLEY $222 231 858 1 318 607 1,23% Acciones
RTW INVESTMENTS, LP $213 689 740 1 267 925 1,18% Acciones
NORTHERN TRUST CORP $212 306 405 1 259 717 1,17% Acciones
Invesco Ltd. $181 565 621 1 077 317 1,00% Acciones
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $164 200 136 974 279 0,91% Acciones
NORGES BANK $164 132 866 973 880 0,91% Acciones
FIRST TRUST ADVISORS LP $155 578 851 923 125 0,86% Acciones
DIMENSIONAL FUND ADVISORS LP $123 525 529 732 877 0,68% Acciones
JACOBS LEVY EQUITY MANAGEMENT, INC $122 375 286 726 112 0,68% Acciones
TWO SIGMA ADVISERS, LP $119 504 823 842 592 0,66% Acciones
Bank of New York Mellon Corp $117 826 993 699 125 0,65% Acciones
Swedbank AB $109 730 107 651 082 0,61% Acciones
VANGUARD FIDUCIARY TRUST CO $109 170 737 647 763 0,60% Acciones
IEQ CAPITAL, LLC $107 913 614 640 304 0,60% Acciones
GOLDMAN SACHS GROUP INC $106 495 877 631 892 0,59% Acciones
BANK OF AMERICA CORP /DE/ $104 382 489 619 352 0,58% Acciones
VICTORY CAPITAL MANAGEMENT INC $104 238 729 618 499 0,58% Acciones
Man Group plc $101 292 738 601 019 0,56% Acciones
ROYAL BANK OF CANADA $98 337 000 583 476 0,54% Acciones
RAYMOND JAMES FINANCIAL INC $97 778 953 580 170 0,54% Acciones
FRANKLIN RESOURCES INC $93 211 316 553 068 0,51% Acciones
UBS Group AG $92 009 492 545 937 0,51% Acciones
Caisse de depot et placement du Quebec $91 002 327 539 961 0,50% Acciones
ARMISTICE CAPITAL, LLC $90 307 457 535 838 0,50% Acciones
AMERIPRISE FINANCIAL INC $84 660 571 502 267 0,47% Acciones
PRIMECAP MANAGEMENT CO/CA/ $82 807 988 491 340 0,46% Acciones
Hood River Capital Management LLC $79 082 184 469 233 0,44% Acciones
Nuveen, LLC $77 408 341 459 301 0,43% Acciones
UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC $75 318 261 571 719 0,42% Acciones
Pictet Asset Management Holding SA $72 751 030 430 635 0,40% Acciones
Rockefeller Capital Management L.P. $62 955 982 373 548 0,35% Acciones
Fiera Capital Corp $62 895 914 373 192 0,35% Acciones
Gotham Asset Management, LLC $62 622 213 371 568 0,35% Acciones
JANUS HENDERSON GROUP PLC $61 515 240 466 977 0,34% Acciones
ALLIANCEBERNSTEIN L.P. $60 767 710 461 270 0,34% Acciones
Vinva Investment Management Ltd $58 838 530 346 109 0,32% Acciones
AustralianSuper Pty Ltd $58 817 535 348 993 0,32% Acciones

Mostrar todos los 825 propietarios institucionales →

Activistas y propietarios del %+ 5 1 tenencia

18

Inversores que presentaron el Anexo 13D de la SEC — propiedad beneficiosa superior al % 5 con la intención de influir en el emisor (participaciones activistas, campañas de la junta directiva, M&A). Cada fila muestra el estado conocido más reciente de la posición de ese declarante.

Declarante Presentado Participación Estado Propósito Presentación
Neurocrine Biosciences, Inc. ×3 presentaciones 24 de febrero de 2023 · Presentación inicial · SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Informantes de la empresa 41 insiders · 22 directivos · 15 consejeros

19
Insider Rol Última actividad Acciones en propiedad Compras 12m Ventas 12m Neto 12m
Kyle Gano Chief Executive Officer 11 de septiembre de 2026 F 154 728 0 3 $-4 872 890
Matt Abernethy Chief Financial Officer 14 de septiembre de 2026 S 42 808 0 1 $-363 289
Timothy Coughlin Chief Financial Officer 6 de febrero de 2017 S 137 961 0 0 $0
David-Alexandre C Gros President & COO 6 de febrero de 2017 A · 0 0 $0
David W. Boyer Chief Corp. Affairs Officer 14 de septiembre de 2026 S 8 722 0 2 $-739 070
Ingrid Delaet Chief Regulatory Officer 11 de septiembre de 2026 F 18 289 0 5 $-3 747 962
Jude Onyia Chief Scientific Officer 11 de septiembre de 2026 F 22 647 0 2 $-3 473 580
Sanjay Chandru Keswani Chief Medical Officer 11 de septiembre de 2026 F 3 281 0 0 $0
Julie Cooke Chief Human Resources Officer 11 de septiembre de 2026 F 24 025 0 5 $-5 770 377
Eric Benevich Chief Commercial Officer 11 de septiembre de 2026 F 67 297 0 2 $-1 238 918
Darin Lippoldt Chief Legal Officer 11 de septiembre de 2026 F 56 793 0 5 $-4 196 071
Eiry Roberts Chief Medical Officer 13 de febrero de 2025 M 35 640 0 0 $0
Malcolm Lloyd-Smith Chief Integration Officer 8 de febrero de 2023 S 42 337 0 0 $0
Dimitri E. Grigoriadis Chief Research Officer 31 de enero de 2022 A 82 273 0 0 $0
Haig P. Bozigian Chief Development Officer 8 de febrero de 2021 A 157 651 0 0 $0
Christopher Flint Obrien Former Chief Medical Officer 5 de febrero de 2018 A 55 946 0 0 $0
VALEUR JENSEN MARGARET E EVP and General Counsel 31 de agosto de 2011 A 118 256 0 0 $0
Richard J Ranieri Sr. VP, Human Resources 27 de febrero de 2008 A 9 667 0 0 $0
Wendall Wierenga EVP, Research & Development 19 de enero de 2006 A 5 023 0 0 $0
Henry Pan Executive VP and CMO 3 de junio de 2005 A 11 216 0 0 $0
Robert J Little SVP, Commercial Operations 18 de febrero de 2005 A · 0 0 $0
SAUNDERS JOHN Vice President Research (Chem) 18 de diciembre de 2003 S 7 966 0 0 $0
Kevin Charles Gorman Consejero 11 de septiembre de 2026 F 517 797 0 1 $-37 824 431
SHERWIN STEPHEN A Consejero 2 de septiembre de 2026 G 14 860 0 5 $-4 132 990
Leslie V Norwalk Consejero 29 de julio de 2026 M 2 430 0 5 $-1 973 882
Johanna Mercier Consejero 27 de mayo de 2026 A 6 853 0 0 $0
William H Rastetter Consejero 27 de mayo de 2026 A 43 678 0 1 $-2 732 760
Christine A Poon Consejero 27 de mayo de 2026 A 4 753 0 0 $0
POPS RICHARD F Consejero 27 de mayo de 2026 A 37 798 0 1 $-2 364 750
LYONS GARY A Consejero 27 de mayo de 2026 A 122 141 0 1 $-2 289 150
MORROW GEORGE J Consejero 27 de mayo de 2026 A 10 386 0 1 $-2 150 550
Alfred Sandrock Consejero 22 de mayo de 2019 A · 0 0 $0
Corinne H Nevinny Consejero 24 de mayo de 2018 A 43 283 0 0 $0
Thomas W Mitchell Consejero 28 de mayo de 2015 A 1 000 0 0 $0
VALE WYLIE W Consejero 25 de mayo de 2011 A 231 372 0 0 $0
Adrian Adams Consejero 30 de junio de 2006 A · 0 0 $0
Shalini Sharp · 27 de mayo de 2026 A 4 088 0 0 $0
MOLLICA JOSEPH A · 22 de mayo de 2017 A 56 042 0 0 $0
HAWRAN PAUL W · 18 de septiembre de 2006 J 132 000 0 0 $0
Lawrence Steinman · 2 de marzo de 2005 S 15 500 0 0 $0
CONLON PAUL J · 16 de diciembre de 2003 S 57 335 0 0 $0

Informantes de las presentaciones SEC Form 3/4/5; neto = solo P/S de mercado abierto

Propiedad de ETFs Mantenido por 104 ETFs

20

El peso refleja solo las tenencias directas de acciones (N-PORT); los fondos apalancados o basados en derivados pueden tener exposición adicional a swaps no mostrada.

Fondo Ponderación Unidades A fecha de Fuente
IBRN · iShares Trust 3,75% 1 793 SH 11 de septiembre de 2026 Diario
PBE · Invesco Exchange-Traded Fund Trust 2,60% 76 511 SH 2 de octubre de 2026 Diario
MCOW · Pacer Funds Trust 2,57% 164 NS 31 de julio de 2026 N-PORT
BUL · Pacer Funds Trust 2,15% 16 896 NS 31 de julio de 2026 N-PORT
CVSM · Elevation Series Trust 2,04% 11 525 NS 31 de julio de 2026 N-PORT
JMID · Janus Detroit Street Trust 1,93% 2 742 NS 31 de julio de 2026 N-PORT
POWA · Invesco Exchange-Traded Self-Indexe… 1,92% 22 570 SH 2 de octubre de 2026 Diario
FGSI · First Trust Exchange-Traded Fund IV 1,90% 236 NS 31 de julio de 2026 N-PORT
ABOT · Abacus FCF ETF Trust 1,90% 460 NS 31 de julio de 2026 N-PORT
XMHQ · Invesco Exchange-Traded Fund Trust 1,74% 667 222 SH 2 de octubre de 2026 Diario
FXH · First Trust Exchange-Traded AlphaDE… 1,67% 105 135 NS 31 de julio de 2026 N-PORT
GRPM · Invesco Exchange-Traded Fund Trust 1,61% 56 862 SH 2 de octubre de 2026 Diario
BBP · ETFis Series Trust I 1,44% 8 494 NS 31 de julio de 2026 N-PORT
CSMD · Professionally Managed Portfolios 1,18% 32 094 NS 31 de julio de 2026 N-PORT
IBB · iShares Trust 1,14% 755 021 SH 11 de septiembre de 2026 Diario
AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… 1,11% 7 516 NS 31 de julio de 2026 N-PORT
JSMD · Janus Detroit Street Trust 1,05% 66 455 NS 31 de julio de 2026 N-PORT
RFG · Invesco Exchange-Traded Fund Trust 1,04% 24 859 SH 2 de octubre de 2026 Diario
IBBQ · Invesco Exchange-Traded Fund Trust … 0,96% 7 190 SH 2 de octubre de 2026 Diario
IVOG · VANGUARD ADMIRAL FUNDS 0,89% 99 214 SH 19 de agosto de 2026 Diario
COWG · Pacer Funds Trust 0,78% 103 520 NS 31 de julio de 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 0,73% 399 NS 31 de julio de 2026 N-PORT
LSEQ · Harbor ETF Trust 0,72% 661 NS 31 de julio de 2026 N-PORT
QQQJ · Invesco Exchange-Traded Fund Trust … 0,72% 59 939 SH 2 de octubre de 2026 Diario
LABU · Direxion Shares ETF Trust 0,71% 20 978 NS 31 de julio de 2026 N-PORT
IQSM · New York Life Investments ETF Trust 0,63% 12 528 NS 31 de julio de 2026 N-PORT
FNY · First Trust Exchange-Traded AlphaDE… 0,63% 21 784 NS 31 de julio de 2026 N-PORT
QLV · FlexShares Trust 0,56% 5 460 NS 31 de julio de 2026 N-PORT
ISCG · iShares Trust 0,52% 31 868 SH 11 de septiembre de 2026 Diario
PTMC · Pacer Funds Trust 0,47% 11 072 NS 31 de julio de 2026 N-PORT
USMV · iShares Trust 0,46% 697 795 SH 11 de septiembre de 2026 Diario
VBK · VANGUARD INDEX FUNDS 0,46% 1 331 820 SH 19 de agosto de 2026 Diario
IVOO · VANGUARD ADMIRAL FUNDS 0,46% 162 408 SH 19 de agosto de 2026 Diario
QVMM · Invesco Exchange-Traded Fund Trust … 0,45% 13 252 SH 2 de octubre de 2026 Diario
SMDX · Tidal Trust III 0,43% 3 374 NS 31 de julio de 2026 N-PORT
BKMC · BNY Mellon ETF Trust 0,42% 16 429 NS 31 de julio de 2026 N-PORT
IWP · iShares Trust 0,39% 480 949 SH 11 de septiembre de 2026 Diario
SDG · iShares Trust 0,38% 4 071 SH 11 de septiembre de 2026 Diario
BBMC · J.P. Morgan Exchange-Traded Fund Tr… 0,36% 44 021 NS 31 de julio de 2026 N-PORT
MIDU · Direxion Shares ETF Trust 0,36% 1 476 NS 31 de julio de 2026 N-PORT
FSMD · FIDELITY COVINGTON TRUST 0,31% 46 187 NS 31 de julio de 2026 N-PORT
FNX · First Trust Exchange-Traded AlphaDE… 0,30% 24 447 NS 31 de julio de 2026 N-PORT
JPME · J.P. Morgan Exchange-Traded Fund Tr… 0,29% 8 053 NS 31 de julio de 2026 N-PORT
COWZ · Pacer Funds Trust 0,25% 283 150 NS 31 de julio de 2026 N-PORT
IYH · iShares Trust 0,25% 57 843 SH 11 de septiembre de 2026 Diario
VHT · VANGUARD WORLD FUND 0,24% 286 599 SH 19 de agosto de 2026 Diario
FHLC · FIDELITY COVINGTON TRUST 0,23% 45 259 NS 31 de julio de 2026 N-PORT
SMMD · iShares Trust 0,21% 52 744 SH 11 de septiembre de 2026 Diario
EUSA · iShares, Inc. 0,20% 25 089 SH 11 de septiembre de 2026 Diario
VB · VANGUARD INDEX FUNDS 0,20% 2 306 077 SH 19 de agosto de 2026 Diario
PWS · Pacer Funds Trust 0,20% 287 NS 31 de julio de 2026 N-PORT
SIZE · iShares Trust 0,20% 5 417 SH 11 de septiembre de 2026 Diario
VXF · VANGUARD INDEX FUNDS 0,19% 1 153 763 SH 19 de agosto de 2026 Diario
FAD · First Trust Exchange-Traded AlphaDE… 0,19% 6 541 NS 31 de julio de 2026 N-PORT
ACWV · iShares, Inc. 0,18% 37 854 SH 11 de septiembre de 2026 Diario
RWK · Invesco Exchange-Traded Fund Trust … 0,13% 11 381 SH 2 de octubre de 2026 Diario
IWR · iShares Trust 0,11% 405 396 SH 11 de septiembre de 2026 Diario
FHEQ · Fidelity Greenwood Street Trust 0,11% 6 157 NS 31 de julio de 2026 N-PORT
ESUM · Strategy Shares 0,10% 1 133 NS 31 de julio de 2026 N-PORT
HEQQ · J.P. Morgan Exchange-Traded Fund Tr… 0,10% 177 NS 31 de julio de 2026 N-PORT
LRND · New York Life Investments ETF Trust 0,10% 2 270 NS 31 de julio de 2026 N-PORT
HELO · J.P. Morgan Exchange-Traded Fund Tr… 0,09% 23 838 NS 31 de julio de 2026 N-PORT
EQAL · Invesco Exchange-Traded Fund Trust … 0,09% 4 828 SH 2 de octubre de 2026 Diario
DFUV · Dimensional ETF Trust 0,08% 70 759 NS 31 de julio de 2026 N-PORT
OMFL · Invesco Exchange-Traded Self-Indexe… 0,07% 23 598 SH 2 de octubre de 2026 Diario
DYNF · BlackRock ETF Trust 0,07% 177 312 SH 11 de septiembre de 2026 Diario
USXF · iShares Trust 0,06% 5 665 SH 11 de septiembre de 2026 Diario
ESMV · iShares Trust 0,05% 26 SH 11 de septiembre de 2026 Diario
GARP · iShares Trust 0,05% 9 869 SH 11 de septiembre de 2026 Diario
DFAC · Dimensional ETF Trust 0,05% 141 631 NS 31 de julio de 2026 N-PORT
DXUV · Dimensional ETF Trust 0,05% 1 484 NS 31 de julio de 2026 N-PORT
DCOR · Dimensional ETF Trust 0,04% 8 569 NS 31 de julio de 2026 N-PORT
IUSG · iShares Trust 0,04% 89 338 SH 11 de septiembre de 2026 Diario
IWF · iShares Trust 0,04% 320 069 SH 11 de septiembre de 2026 Diario
VONG · VANGUARD SCOTTSDALE FUNDS 0,04% 134 662 SH 19 de agosto de 2026 Diario
ESGV · VANGUARD WORLD FUND 0,03% 22 375 SH 19 de agosto de 2026 Diario
TILT · FlexShares Trust 0,03% 3 888 NS 31 de julio de 2026 N-PORT
DFAU · Dimensional ETF Trust 0,03% 20 775 NS 31 de julio de 2026 N-PORT
RECS · Columbia ETF Trust I 0,02% 8 549 NS 31 de julio de 2026 N-PORT
DFUS · Dimensional ETF Trust 0,02% 28 885 NS 31 de julio de 2026 N-PORT
IYY · iShares Trust 0,02% 4 355 SH 11 de septiembre de 2026 Diario
IWB · iShares Trust 0,02% 68 459 SH 11 de septiembre de 2026 Diario
ITOT · iShares Trust 0,02% 131 068 SH 11 de septiembre de 2026 Diario
IWS · iShares Trust 0,02% 20 508 SH 11 de septiembre de 2026 Diario
IWV · iShares Trust 0,02% 27 012 SH 11 de septiembre de 2026 Diario
PBUS · Invesco Exchange-Traded Fund Trust … 0,02% 16 531 SH 2 de octubre de 2026 Diario
VTI · VANGUARD INDEX FUNDS 0,02% 3 193 839 SH 19 de agosto de 2026 Diario
VONE · VANGUARD SCOTTSDALE FUNDS 0,02% 16 227 SH 19 de agosto de 2026 Diario
VTHR · VANGUARD SCOTTSDALE FUNDS 0,02% 8 342 SH 19 de agosto de 2026 Diario
PRF · Invesco Exchange-Traded Fund Trust 0,02% 11 591 SH 2 de octubre de 2026 Diario
TOK · iShares Trust 0,02% 249 SH 11 de septiembre de 2026 Diario
URTH · iShares, Inc. 0,02% 8 440 SH 11 de septiembre de 2026 Diario
ACWI · iShares Trust 0,01% 30 548 SH 11 de septiembre de 2026 Diario
DFLV · Dimensional ETF Trust 0,01% 4 926 NS 31 de julio de 2026 N-PORT
DFVX · Dimensional ETF Trust 0,01% 323 NS 31 de julio de 2026 N-PORT
VT · VANGUARD INTERNATIONAL EQUITY INDEX… 0,01% 85 082 SH 19 de agosto de 2026 Diario
VONV · VANGUARD SCOTTSDALE FUNDS 0,01% 8 319 SH 19 de agosto de 2026 Diario
FYEE · Fidelity Greenwood Street Trust 0,01% 110 NS 31 de julio de 2026 N-PORT
REVS · Columbia ETF Trust I 0,01% 124 NS 31 de julio de 2026 N-PORT
IWD · iShares Trust 0,01% 30 627 SH 11 de septiembre de 2026 Diario
IJH · iShares Trust · 3 528 125 SH 11 de septiembre de 2026 Diario
IJK · iShares Trust · 582 451 SH 11 de septiembre de 2026 Diario
XJH · iShares Trust · 13 736 SH 8 de septiembre de 2026 Diario
ISCB · iShares Trust · 4 526 SH 11 de septiembre de 2026 Diario

NBIX Consenso de analistas Opiniones de analistas alcistas y bajistas, precio objetivo a 12 meses, potencial alcista

21
calificación · 36 analistas COMPRA
Objetivo mediano $214.00 +49,5%
14 38,9% Compra fuerte
17 47,2% Compra
5 13,9% Mantener
0 0,0% Venta
0 0,0% Venta fuerte

Precio objetivo a 12 meses

29 analistas · 2026-10-03

Objetivo medio $207.81 +45,1%

← Por Debajo de Todos los Objetivos Precio Actual $143.18
Mín$164.00 Media$207.81 Máx$253.00

Comparación de pares (subindustria GICS) Métricas clave frente a competidores del sector

22

Base del ejercicio fiscal, precios al cierre del último ejercicio fiscal de cada empresa.

Ticker Capitalización Bursátil P/E Ingresos interanuales Margen Neto ROE Margen Bruto
NBIX $14.20B 30.4 21.4% 16.7% 16.1% ·
INSM $37.29B -27.1 66.7% -210.5% -128.4% ·
INCY $19.60B 15.4 21.2% 25.0% 27.6% ·
UTHR $21.27B 17.5 10.6% 41.9% 18.7% 87.9%
EXEL $11.44B 15.7 7.0% 33.7% 37.3% ·
SMMT $13.56B -12.1 · · -235.1% ·
BBIO $14.90B -20.2 126.3% -146.0% 41.2% ·
TWST $1.71B -21.6 20.3% -20.6% -17.0% ·
HALO $7.93B 26.3 37.5% 22.7% 166.1% ·
MDGL $13.30B -45.3 432.1% -30.1% -44.4% ·

Últimas noticias Noticias recientes que mencionan a esta empresa

23
Opciones de Diciembre de 2027 Ahora Disponibles para Neurocrine Biosciences (NBIX) Nasdaq · 5 meses, 3 semanas atrás Mercado de valores hoy, 6 de abril: Soleno Therapeutics sube tras acuerdo de adquisición en efectivo de $2.9 mil millones Nasdaq · 5 meses, 3 semanas atrás Neurocrine se Adquiere Soleno Por 2.900 Millones de Dólares en Acuerdo en Efectivo; La Acción de Soleno Aumenta en Premercado Nasdaq · 5 meses, 3 semanas atrás

Señales de trading Señales recientes de compra/venta con precio de entrada y ratio riesgo/recompensa

25
BLUECHIP_DIP Stop out Sep 8
riesgo 1 recompensa 1,67
entrada $156.04 R:R 1,67
BLUECHIP_DIP Stop out Ago 6
riesgo 1 recompensa 2,78
entrada $161.50 R:R 2,78
BLUECHIP_DIP Expirada Abr 28
riesgo 1 recompensa 5,00
entrada $129.88 R:R 5,00
BLUECHIP_DIP Stop out Abr 20
riesgo 1 recompensa 4,80
entrada $132.67 R:R 4,80
BLUECHIP_DIP Stop out Abr 9
riesgo 1 recompensa 5,00
entrada $132.79 R:R 5,00

Ninguna señal abierta en este momento — ninguna tarjeta está completada, y eso es honesto.

Mis Métricas Tu lista de seguimiento personal — filas seleccionadas de Fundamentales Completos

26

Seleccione las métricas que le importan: haga clic en el + junto a cualquier fila en Fundamentales completos arriba.

Tu selección se guarda y te sigue en todos los tickers.

Fuente: SEC 10-Q presentada el Jul 31, 2026